Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MGTX |
---|---|---|
09:32 ET | 625 | 5.42 |
09:36 ET | 250 | 5.435 |
09:38 ET | 100 | 5.39 |
09:39 ET | 100 | 5.39 |
09:41 ET | 200 | 5.39 |
09:43 ET | 100 | 5.4 |
09:45 ET | 100 | 5.4 |
09:48 ET | 1100 | 5.4 |
09:50 ET | 100 | 5.4 |
09:54 ET | 200 | 5.39 |
09:56 ET | 700 | 5.39 |
09:57 ET | 216 | 5.39 |
09:59 ET | 2250 | 5.375 |
10:01 ET | 500 | 5.37 |
10:03 ET | 200 | 5.37 |
10:06 ET | 564 | 5.38 |
10:08 ET | 3031 | 5.38 |
10:10 ET | 100 | 5.38 |
10:12 ET | 100 | 5.38 |
10:15 ET | 300 | 5.39 |
10:17 ET | 1200 | 5.39 |
10:21 ET | 422 | 5.38 |
10:24 ET | 700 | 5.38 |
10:26 ET | 900 | 5.39 |
10:30 ET | 200 | 5.39 |
10:32 ET | 885 | 5.39 |
10:35 ET | 2200 | 5.39 |
10:37 ET | 200 | 5.39 |
10:46 ET | 200 | 5.38 |
10:48 ET | 100 | 5.38 |
10:51 ET | 200 | 5.37 |
10:55 ET | 2688 | 5.38 |
10:57 ET | 100 | 5.38 |
11:00 ET | 100 | 5.38 |
11:02 ET | 1200 | 5.41 |
11:06 ET | 900 | 5.42 |
11:15 ET | 100 | 5.39 |
11:20 ET | 100 | 5.39 |
11:24 ET | 100 | 5.39 |
11:26 ET | 956 | 5.405 |
11:27 ET | 300 | 5.405 |
11:29 ET | 100 | 5.39 |
11:33 ET | 1060 | 5.36 |
11:38 ET | 100 | 5.36 |
11:42 ET | 100 | 5.36 |
11:45 ET | 100 | 5.36 |
11:47 ET | 300 | 5.39 |
11:51 ET | 200 | 5.38 |
11:54 ET | 840 | 5.38 |
11:56 ET | 396 | 5.39 |
11:58 ET | 100 | 5.38 |
12:02 ET | 1100 | 5.38 |
12:03 ET | 1100 | 5.385 |
12:05 ET | 779 | 5.35 |
12:07 ET | 3400 | 5.37 |
12:09 ET | 1100 | 5.375 |
12:14 ET | 100 | 5.37 |
12:18 ET | 2000 | 5.3519 |
12:20 ET | 144 | 5.3899 |
12:21 ET | 700 | 5.39 |
12:23 ET | 200 | 5.38 |
12:34 ET | 100 | 5.37 |
12:36 ET | 750 | 5.36 |
12:38 ET | 200 | 5.37 |
12:39 ET | 300 | 5.365 |
12:41 ET | 100 | 5.36 |
12:45 ET | 800 | 5.36 |
12:48 ET | 1300 | 5.36 |
12:50 ET | 603 | 5.36 |
12:56 ET | 844 | 5.364 |
12:57 ET | 100 | 5.355 |
12:59 ET | 100 | 5.36 |
01:03 ET | 200 | 5.37 |
01:10 ET | 700 | 5.38 |
01:17 ET | 200 | 5.37 |
01:21 ET | 100 | 5.3817 |
01:24 ET | 2200 | 5.4 |
01:35 ET | 200 | 5.39 |
01:39 ET | 100 | 5.39 |
01:44 ET | 100 | 5.39 |
01:51 ET | 100 | 5.38 |
01:53 ET | 100 | 5.38 |
01:55 ET | 200 | 5.38 |
01:57 ET | 100 | 5.38 |
02:00 ET | 200 | 5.395 |
02:04 ET | 300 | 5.39 |
02:06 ET | 300 | 5.38 |
02:09 ET | 100 | 5.37 |
02:13 ET | 700 | 5.37 |
02:15 ET | 400 | 5.36 |
02:18 ET | 100 | 5.36 |
02:20 ET | 100 | 5.35 |
02:27 ET | 100 | 5.35 |
02:29 ET | 100 | 5.365 |
02:31 ET | 100 | 5.35 |
02:36 ET | 2180 | 5.33 |
02:38 ET | 2599 | 5.38 |
02:42 ET | 100 | 5.37 |
02:45 ET | 400 | 5.39 |
02:47 ET | 200 | 5.395 |
02:56 ET | 100 | 5.37 |
03:02 ET | 100 | 5.34 |
03:03 ET | 600 | 5.35 |
03:05 ET | 400 | 5.34 |
03:07 ET | 1700 | 5.355 |
03:09 ET | 1390 | 5.37 |
03:14 ET | 274 | 5.35 |
03:16 ET | 637 | 5.38 |
03:20 ET | 100 | 5.35 |
03:23 ET | 100 | 5.35 |
03:25 ET | 100 | 5.35 |
03:27 ET | 400 | 5.35 |
03:30 ET | 503 | 5.35 |
03:32 ET | 300 | 5.34 |
03:34 ET | 300 | 5.32 |
03:36 ET | 184 | 5.335 |
03:38 ET | 200 | 5.32 |
03:39 ET | 300 | 5.32 |
03:41 ET | 2200 | 5.3399 |
03:43 ET | 400 | 5.31 |
03:45 ET | 400 | 5.315 |
03:48 ET | 100 | 5.315 |
03:50 ET | 400 | 5.315 |
03:52 ET | 10844 | 5.26 |
03:54 ET | 436 | 5.295 |
03:56 ET | 6521 | 5.27 |
03:57 ET | 1090 | 5.27 |
03:59 ET | 3473 | 5.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
MeiraGTx Holdings PLC | 344.1M | -3.3x | --- |
TScan Therapeutics Inc | 341.6M | -2.7x | --- |
Iteos Therapeutics Inc | 397.9M | -3.4x | --- |
Cartesian Therapeutics Inc | 333.7M | -0.4x | --- |
Rani Therapeutics Holdings Inc | 344.6M | -5.9x | --- |
Renovaro Inc | 347.7M | -3.2x | --- |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $344.1M |
---|---|
Revenue (TTM) | $14.0M |
Shares Outstanding | 63.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-1.58 |
Book Value | $2.17 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | 24.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -977.82% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.